Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Jan 23, 2026

Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study

Dec 5, 2025

(R) Cantargia Provides Update on Overall Survival Data from TRIFOUR

Nov 19, 2025

(R) Cantargia Publishes Interim Report for January to September 2025

Nov 12, 2025

(R) Cantargia presents Nomination Committee ahead of 2026 AGM

Nov 5, 2025

Invitation to the Presentation of Cantargia’s Interim Report January-September 2025

Oct 23, 2025

Cantargia to Participate in Upcoming Conferences

Oct 2, 2025

(R) Cantargia appoints Dr. Wolfram Dempke as Chief Medical Officer

Oct 1, 2025

Cantargia presents data at an AACR Conference strengthening IL1RAP as a targetable hallmark in PDAC

Sep 11, 2025

(R) Cantargia closes the acquisition of CAN10 by Otsuka

Aug 27, 2025

Cantargia granted important US patent for nadunolimab

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye